Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA,
Bellevue Dermatology Clinic and Research Center, Bellevue, Washington, USA.
Dermatology. 2020;236(5):393-412. doi: 10.1159/000507323. Epub 2020 May 14.
Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients' quality of life. While high-quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to the recent publication of multiple international treatment guidelines for HS.
This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/weak recommendation or higher across all major guidelines. This review describes the appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist.
化脓性汗腺炎（HS）是一种慢性疼痛性皮肤病，严重影响患者的生活质量。虽然 HS 疗法的高质量试验仍然有限，但有关最佳治疗实践的医学知识正在迅速发展，导致最近发布了多个 HS 国际治疗指南。
本综述比较了国际 HS 治疗指南，描述了常见和新兴 HS 疗法的有效性证据，并为将基于证据的 HS 护理纳入实践提供了指导。尽管国际 HS 指南中提到了超过 50 种医疗和程序治疗方法，但只有阿达木单抗和英夫利昔单抗在所有主要指南中都获得 B/弱推荐或更高的评级。本综述描述了最常用于 HS 的常见医疗和程序治疗的适当患者选择和有效性。它还包括关于医学治疗的咨询、剂量和持续时间的建议，以及皮肤科医生的操作视频。
